Caxton Associates (New York)’s Editas Medicine EDIT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-114,363
| Closed | -$390K | – | 539 |
|
|
2024
Q3 | $390K | Sell |
114,363
-14,147
| -11% | -$48.2K | 0.01% | 399 |
|
|
2024
Q2 | $600K | Buy |
+128,510
| New | +$600K | 0.02% | 319 |
|
|
2024
Q1 | – | Sell |
-32,553
| Closed | -$330K | – | 481 |
|
|
2023
Q4 | $330K | Sell |
32,553
-28,670
| -47% | -$290K | 0.02% | 385 |
|
|
2023
Q3 | $478K | Buy |
61,223
+27,678
| +83% | +$216K | 0.07% | 251 |
|
|
2023
Q2 | $276K | Sell |
33,545
-74,163
| -69% | -$610K | 0.04% | 354 |
|
|
2023
Q1 | $781K | Buy |
107,708
+93,375
| +651% | +$677K | 0.12% | 187 |
|
|
2022
Q4 | $127K | Buy |
+14,333
| New | +$127K | 0.01% | 389 |
|
|
2022
Q3 | – | Sell |
-17,101
| Closed | -$202K | – | 500 |
|
|
2022
Q2 | $202K | Buy |
+17,101
| New | +$202K | 0.02% | 449 |
|